Status:
COMPLETED
Dexmedetomidine As An Adjuvant To Bupivacaine 0.1% in Labor Analgesia
Lead Sponsor:
Services Institute of Medical Sciences, Pakistan
Conditions:
Labor Analgesia
Labor Pain
Eligibility:
FEMALE
20-40 years
Phase:
NA
Brief Summary
Females who have experienced normal labor for child birth have claimed it to be most difficult and distressing moments of their life due to excruciating and unbearable pain. Provision of effective and...
Detailed Description
Objectives of this study are to evaluate the efficacy of adding dexmedetomidine in labor epidurals with 0.1% bupivacaine in females undergoing normal vaginal delivery. OPERATIONAT DEFINITIONS: 1. On...
Eligibility Criteria
Inclusion
- Patients in 37 or more weeks of pregnancy,
- having a single pregnancy with vertex presentation
- without any significant systemic disease will be included in the study.
Exclusion
- Patients with mal-presentation
- twin pregnancy
- preeclampsia,
- uncontrolled systemic comorbidities
- diabetes, renal, hepatic, or cardiac.
- bleeding, diathesis, body mass index (BMl) more than 35 kg/m2
- known allergy to any of the study drugs will be excluded from the study.
Key Trial Info
Start Date :
November 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2023
Estimated Enrollment :
165 Patients enrolled
Trial Details
Trial ID
NCT06550414
Start Date
November 1 2022
End Date
May 1 2023
Last Update
August 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hameed Lateef Hospital
Lahore, Punjab Province, Pakistan, 042